Prostate

TITRE (EN) Pelvic Nodes Ultra-Hypo Fractionated Versus Conventionally Fractionated IMRT With HDR Brachytherapy Boost in Prostate Cancer: A Collaborative Multi-institutional Non-inferiority Phase 3 Trial.
PROTOCOLE ID PCS-XI
CLINICAL TRIAL.gov ID NCT05820633
TYPE(S) DE CANCER Prostate
PHASE Phase III
TYPE D'ÉTUDE Clinique
INSTITUTION HOPITAL MAISONNEUVE-ROSEMONT
5415 boul. de l'Assomption
(514) 252-3400
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) Peter Vavassis
COORDONATEUR(RICE) Lys Fernet
lys.fernet.cemtl@ssss.gouv.qc.ca
514-252-3400 poste 3227
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Histopathologically confirmed adenocarcinoma of the prostate.
  • All clinical stages with lymph node involvement risk needing pelvis RT.
  • Stage Mx or M0.
  • Unfavorable Intermediate, high or very high-risk disease according to NCCN guidelines.
  • Having the ability to give free and informed consent.
CRITÈRES D'EXCLUSION (EN)
  • Clinical stage M1.
  • IPSS Score > 20 with alpha-blocking medication.
  • Prior pelvic radiotherapy,
  • History of active collagenosis (Lupus, Scleroderma, Dermatomyositis).
  • Past history of Inflammatory Bowell Disease.
  • Bilateral hip prosthesis.